Bio-hybrid material, production method therefor, and stent

Patent metadata

Field	Value
Publication number	US-9428588-B2
Application number	US-201113989279-A
Country	US
Kind code	B2
Filing date	Nov 24, 2011
Priority date	Nov 26, 2010
Publication date	Aug 30, 2016
Grant date	Aug 30, 2016

Abstract

Provided is a bio-hybrid material that does not cause elution of nickel ions and has an excellent endothelialization ability, a production method therefor, and a stent. The bio-hybrid material ( 101 ) used includes an alloy part ( 11 ) free of Ni, an organic acid ( 12 ) having two or more active esters, and a cytokine ( 13 ). The alloy part ( 11 ) free of Ni forms an ester bond with the organic acid ( 12 ), and the organic acid ( 12 ) and the cytokine ( 13 ) are immobilized via an amide bond.

First claim

The invention claimed is:

1. A bio-hybrid material comprising:
an alloy part free of Ni;
an organic acid having three or more active ester groups; and
a cytokine,
wherein the alloy part free of Ni forms an ester bond with the organic acid through one of the three or more active ester groups of the organic acid, and the organic acid and the cytokine are immobilized via an amide bond through active ester groups free of the ester bond with the alloy part free of Ni among the three or more active ester groups of the organic acid.

2. The bio-hybrid material according to claim 1 , wherein the cytokine is one selected from a group consisting of Vascular Endothelial Growth Factor (VEGF), Epithelial Growth Factor (EGF), Fibroblast Growth Factor (FGF), Hepatocyte Growth Factor (HGF), Platelet-Derived Growth Factor (PDGF), and Bone Morphogenetic Protein (BMP).

3. The bio-hybrid material according to claim 1 , wherein the organic acid having three or more active ester groups is one selected from a group consisting of citric acid, oxalacetic acid, cis-aconitic acid, 2-ketoglutaric acid, and any derivative thereof.

4. The bio-hybrid material according to claim 1 , wherein the alloy part free of Ni is an alloy containing two or more elements selected from a group consisting of Fe, Mo, Co, and Cr.

5. The bio-hybrid material according to claim 4 , wherein the alloy contains nitrogen in an amount ranging from 0.5 wt % to 1 wt %.

6. The bio-hybrid material according to claim 2 , wherein the organic acid having three or more active ester groups is one selected from a group consisting of citric acid, oxalacetic acid, cis-aconitic acid, 2-ketoglutaric acid, and any derivative thereof.

7. The bio-hybrid material according to claim 2 , wherein the alloy part free of Ni is an alloy containing two or more elements selected from a group consisting of Fe, Mo, Co, and Cr.

8. The bio-hybrid material according to claim 3 , wherein the alloy part free of Ni is an alloy containing two or more elements selected from a group consisting of Fe, Mo, Co, and Cr.

9. The bio-hybrid material according to claim 6 , wherein the alloy part free of Ni is an alloy containing two or more elements selected from a group consisting of Fe, Mo, Co, and Cr.

10. The bio-hybrid material according to claim 7 , wherein the alloy contains nitrogen in an amount ranging from 0.5 wt % to 1 wt %.

11. The bio-hybrid material according to claim 8 , wherein the alloy contains nitrogen in an amount ranging from 0.5 wt % to 1 wt %.

12. The bio-hybrid material according to claim 9 , wherein the alloy contains nitrogen in an amount ranging from 0.5 wt % to 1 wt %.

13. The bio-hybrid material according to claim 1 , wherein the alloy part free of Ni as an alloy containing an element selected from a group consisting of Ti, B, and Nb.

14. The bio-hybrid material according to claim 4 , wherein the alloy part free of Ni as an alloy containing an element selected from a group consisting of Ti, B, and Nb.

15. The bio-hybrid material according to claim 5 , wherein the alloy part free of Ni as an alloy containing an element selected from a group consisting of Ti, B, and Nb.

16. A stent comprising the bio-hybrid material according to claim 1 .

17. A stent comprising the bio-hybrid material according to claim 2 .

18. A bio-hybrid material comprising:
an alloy part free of Ni having a hydroxyl group on a surface;
an organic acid having three or more active ester groups; and
a cytokine,
wherein the alloy part free of Ni forms an ester bond with the organic acid through one of the three or more active ester groups of the organic acid, and the organic acid and the cytokine are immobilized via an amide bond through active ester groups free of the ester bond with the ally part free of Ni among the three or more active ester groups of the organic acid.

19. A bio-hybrid material comprising:
an alloy part free of Ni having a hydroxyl group on a surface;
an organic acid having three or more succinimidyl ester groups; and
a cytokine,
wherein the alloy part free of Ni forms an ester bond with the organic acid through one of the three or more active ester groups of the organic acid, and the organic acid and the cytokine are immobilized via an amide bond through active ester groups free of the ester bond with the ally part free of Ni among the three or more active ester groups of the organic acid.

Assignees

• Taguchi Tetsushi
• Sasaki Makoto
• Katada Yasuyuki
• Nat Inst For Materials Science

Inventors

• Taguchi Tetsushi
• Sasaki Makoto
• Katada Yasuyuki

Classifications

• A61L31/16

  Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} · CPC title

• A61L2300/414

  Growth factors · CPC title

• A61L31/022 Primary

  Metals or alloys · CPC title

• A61F2/82

  Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents (stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07) · CPC title

• A61L2300/426

  Immunomodulating agents, i.e. cytokines, interleukins, interferons · CPC title